AXL and non-small cell lung carcinoma: In the absence of the EGFR T790M mutation or MET activation, Zhang et al. found increased AXL activation and evidence for EMT in several in vitro and in vivo EGFR-mutant NSCLC models with acquired resistance to erlotinib [87].